Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Cancer's evasion of cell death limits treatment efficacy.
• The BCL2 antagonist venetoclax validates targeting apoptotic pathways.
• Varied responses to cell death modulators necessitate refined strategies.

Purpose of the Study:

• To review emerging concepts in targeting cancer cell death pathways.
• To propose a shift in focus from pre-treatment to treatment-induced apoptotic dependencies.
• To guide the precise deployment of novel pharmacologic agents for cancer treatment.

Main Methods:

• Review of preclinical and clinical studies on pharmacologic cell death modulators.
• Analysis of emerging concepts in targeting apoptotic pathways.
• Synthesis of observations to propose new therapeutic strategies.

Main Results:

• Targeting antiapoptotic family members shows efficacy in some cancers but infrequent responses, especially in solid tumors.
• Lack of predictive biomarkers for patient selection is a significant challenge.
• Adaptive resistance mechanisms limit durable responses to current therapies.

Conclusions:

• Focusing on treatment-induced changes in apoptotic dependency is crucial for effective cancer therapy.
• Precision functional approaches are needed to overcome adaptive resistance.
• Targeting evolving apoptotic dependencies will enhance durable responses to various cancer treatments.